AstraZeneca
AZN
1,015 hedge funds and large institutions have $34.8B invested in AstraZeneca in 2022 Q2 according to their latest regulatory filings, with 113 funds opening new positions, 310 increasing their positions, 356 reducing their positions, and 68 closing their positions.
66% more first-time investments, than exits
New positions opened: 113 | Existing positions closed: 68
41% more funds holding in top 10
Funds holding in top 10: 17 → 24 (+7)
3% more funds holding
Funds holding: 981 → 1,015 (+34)
2% more capital invested
Capital invested by funds: $34.2B → $34.8B (+$587M)
0.39% more ownership
Funds ownership: 16.67% → 17.06% (+0.39%)
13% less repeat investments, than reductions
Existing positions increased: 310 | Existing positions reduced: 356
15% less call options, than puts
Call options by funds: $386M | Put options by funds: $457M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$546M |
| 2 |
Morgan Stanley
New York
|
+$347M |
| 3 |
BlackRock
New York
|
+$293M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$157M |
| 5 |
DCP
DSM Capital Partners
Palm Beach Gardens,
Florida
|
+$115M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$545M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$194M |
| 3 |
HSBC Holdings
London,
United Kingdom
|
-$101M |
| 4 |
SIG
Senator Investment Group
New York
|
-$99.5M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$88.2M |
AZN Hedge Fund Activity: Q2 2022 in Review
1,015 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2022, worth a combined $34.8B — up 1.7% from $34.2B a quarter earlier.
Buyers outnumbered sellers: 113 funds opened new AZN positions and 68 closed out — a net gain of 45 holders — while 310 added to existing stakes and 356 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $546M. The largest seller was T. Rowe Price Associates, cutting an estimated $545M.
- 1,015 institutional investors held AstraZeneca (AZN) as of Q2 2022, up from 981 in Q1 2022.
- Funds reported $34.8B of AstraZeneca stock for Q2 2022, up 1.7% quarter-over-quarter.
- 113 funds opened new AstraZeneca positions in Q2 2022 and 68 closed out, a net change of +45 holders.
- The largest AstraZeneca buyer in Q2 2022 was Fidelity Investments, an estimated $546M added.
- The largest AstraZeneca seller in Q2 2022 was T. Rowe Price Associates, an estimated $545M sold.
Based on aggregated 13F filings for Q2 2022.